Compare PARK & RPID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PARK | RPID |
|---|---|---|
| Founded | 1972 | 2006 |
| Country | United States | United States |
| Employees | 1212 | N/A |
| Industry | Misc Health and Biotechnology Services | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 94.5M | 102.6M |
| IPO Year | N/A | 2021 |
| Metric | PARK | RPID |
|---|---|---|
| Price | $18.50 | $2.06 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 22.5K | ★ 231.6K |
| Earning Date | 05-13-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 2.78 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $33,587,000.00 |
| Revenue This Year | $7.06 | $19.12 |
| Revenue Next Year | $6.17 | $18.42 |
| P/E Ratio | $6.47 | ★ N/A |
| Revenue Growth | N/A | ★ 19.74 |
| 52 Week Low | $12.29 | $1.66 |
| 52 Week High | $22.68 | $4.94 |
| Indicator | PARK | RPID |
|---|---|---|
| Relative Strength Index (RSI) | 46.65 | 58.29 |
| Support Level | $18.81 | $1.98 |
| Resistance Level | $21.06 | $2.17 |
| Average True Range (ATR) | 1.29 | 0.16 |
| MACD | -0.15 | 0.01 |
| Stochastic Oscillator | 17.29 | 67.86 |
Park Dental Partners Inc is a dental resource organization (DRO) operating through its subsidiary. It Provides comprehensive business support services including clinical team members, administrative personnel, facilities and equipment to its affiliated general and multi-specialty dental practices throughout Minnesota and Wisconsin. Its network of affiliated dental practices provides both general and specialty dental services, including oral surgery, periodontics, pediatric dentistry, prosthodontics, endodontics, and orthodontics, under long-term agreements with initial terms of 30-years, with automatic 5-year renewals.
Rapid Micro Biosystems Inc is a life sciences technology company. Its technology uses a sensitive camera and the natural autofluorescence of living cells to identify and quantify microbial growth faster and more accurately than the traditional method, which relies on the human eye. The company develops, manufactures, markets, and sells Growth Direct systems (Systems), proprietary consumables, laboratory information management system (LIMS) connection, and other software and services to address rapid microbial analysis used for quality control in the manufacture of pharmaceuticals, medical devices, and personal care products. Geographically, it generates maximum revenue from the United States, and the rest from Switzerland, Germany, Japan, and all other countries.